TY - JOUR
T1 - Accelerated and blastic phases of chronic myelogenous leukemia
AU - Giles, Francis J.
AU - Cortes, Jorge E.
AU - Kantarjian, Hagop M.
AU - O'Brien, Susan M.
PY - 2004/6
Y1 - 2004/6
N2 - Although the mechanisms of CML transformation remain poorly understood, recent therapeutic advances moderately have improved the prognosis of patients in AP and BP. Treatment with IFN-αbased regimens are minimally effective for patients in AP and ineffective for those in BP. Imatinib mesylate has a significant but generally transient response rate in patients in AP and BP. Hope for progress in this area lies mainly in the development of novel targeted therapies. The more promising agents that are being investigated include decitabine, HHT, troxacitabine, clofarabine, farnesyl transferase inhibitors, histone deacetylase inhibitors, and the VEGF and mTOR inhibitors. Many of these approaches may be synergistic with imatinib or the more powerful abl or Src inhibitors that are in development.
AB - Although the mechanisms of CML transformation remain poorly understood, recent therapeutic advances moderately have improved the prognosis of patients in AP and BP. Treatment with IFN-αbased regimens are minimally effective for patients in AP and ineffective for those in BP. Imatinib mesylate has a significant but generally transient response rate in patients in AP and BP. Hope for progress in this area lies mainly in the development of novel targeted therapies. The more promising agents that are being investigated include decitabine, HHT, troxacitabine, clofarabine, farnesyl transferase inhibitors, histone deacetylase inhibitors, and the VEGF and mTOR inhibitors. Many of these approaches may be synergistic with imatinib or the more powerful abl or Src inhibitors that are in development.
UR - http://www.scopus.com/inward/record.url?scp=3242748217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242748217&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2004.03.005
DO - 10.1016/j.hoc.2004.03.005
M3 - Review article
C2 - 15271404
AN - SCOPUS:3242748217
SN - 0889-8588
VL - 18
SP - 753
EP - 774
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 3
ER -